The aim of this report was to present a case of interference on prothrombin time (PT) test that directed further laboratory diagnostics and resulted with final detection of monoclonal gammopathy in an 88-year old man. Routine coagulation testing during medical examination at Emergency Department revealed unmeasurable PT (< 7% activity) and activated partial thromboplastin time (aPTT) within reference range. After repeated sampling for coagulation testing, PT was unmeasurable again, as well as fibrinogen level (< 0.8 g/L), thrombin time (TT) was significantly prolonged (107 seconds) and aPTT was within reference range. In both plasma samples refrigerated at 4 ˚C overnight, white gelatinous precipitate was visible between the cell and plasma layers and the presence of monoclonal protein (M-protein) was suggested in our patient. Further laboratory diagnostics revealed total serum proteins at concentration of 123 g/L and the presence of M-protein IgG lambda (λ) at concentration of 47.1 g/L. These results suggested monoclonal gammopathy as an underlying pathophysiological condition in our patient. Activities of coagulation factors II, V, VII and X were within reference ranges or increased. These results and correction of unmeasurable PT result to 67% in mixing test with commercial normal plasma suggest in vitro rather than in vivo interference of M-protein on PT result. In contrast, significantly prolonged TT results in all analysed samples suggest impact of M-protein on this global coagulation test due to possible effect on fibrin polymerization.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910265PMC
http://dx.doi.org/10.11613/BM.2016.028DOI Listing

Publication Analysis

Top Keywords

interference m-protein
8
prothrombin time
8
time test
8
laboratory diagnostics
8
monoclonal gammopathy
8
coagulation testing
8
aptt reference
8
reference range
8
m-protein prothrombin
4
time
4

Similar Publications

Background: Therapeutic monoclonal antibodies (t-mAbs) may interfere with electrophoresis-based methods used to monitor multiple myeloma (MM), which can create inaccurate results. Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry is an alternative to gels distinguishing between endogenous M-proteins and t-mAbs based on molecular mass.

Methods: Serum samples (n = 109) from 34 MM patients receiving Dara-KRd were collected 14 or 28 days postdaratumumab administration.

View Article and Find Full Text PDF

An interference in bilirubin detection: Pulmonary marginal zone lymphoma presenting monoclonal cryoglobulin.

Clin Chim Acta

December 2024

Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400044, China. Electronic address:

Marginal zone lymphoma (MZL) of the lung is an indolent B-cell lymphoma. The peripheral blood of most patients with pulmonary MZL contains low or undetectable monoclonal immunoglobulin (M protein) levels. In this case, the clinical laboratory discovered that the pulmonary MZL patient not only associated with high concentration of monoclonal IgG-type protein but also exhibited obvious gel formation characteristics that interfered with clinical biochemistry tests.

View Article and Find Full Text PDF
Article Synopsis
  • The study emphasizes the significance of viral-host protein interactions in cell infection and how tagging viral proteins with markers like HA, His, and Flag helps in studying these interactions.
  • A new reverse genetic system was successfully developed to produce Newcastle disease virus (NDV) with tagged structural proteins, allowing for efficient study of protein interactions without the need for specific antibodies.
  • This system enabled the identification of host proteins interacting with the HA-tagged M protein, paving the way for deeper understanding of NDV and its interactions with host proteins.
View Article and Find Full Text PDF
Article Synopsis
  • CAR T-cell therapies have improved the detection of M-protein in patients with relapsed/refractory multiple myeloma (RRMM), even when traditional methods fail.
  • Quantitative immunoprecipitation mass spectrometry (QIP-MS) provides highly sensitive measurements of serum M-protein and can identify interferences from monoclonal antibody therapies.
  • QIP-MS showed a high level of agreement with serum immunofixation, but less so with bone marrow-based flow cytometry, and it appears to be a valuable non-invasive tool for monitoring treatment responses in multiple myeloma patients.
View Article and Find Full Text PDF

Evaluating the HYDRASHIFT 2/4 Daratumumab assay: a powerful approach to assess treatment response in multiple myeloma.

Clin Chem Lab Med

October 2024

Department of Laboratory Medicine and Genetics, 36626 Samsung Medical Center , Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Objectives: This study evaluates the HYDRASHIFT assay's effectiveness in mitigating daratumumab interference on serum protein tests during multiple myeloma (MM) treatment, aiming to ensure an accurate assessment of treatment response.

Methods: We analyzed 113 serum samples from 68 MM patients undergoing daratumumab treatment, employing both standard IF and the HYDRASHIFT assay. The assay's precision was determined through intra-day and inter-day variability assessments, while its specificity was verified using serum samples devoid of daratumumab.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!